

## **Causal Effect of *Helicobacter Pylori* Infection on Coronary**

### **Heart Disease is mediated by Body Mass Index: A Mendelian Randomization Study**

Bing Li, MD, <sup>1</sup>Yaoting Zhang, MD, <sup>1</sup>Yang Zheng, MD, PhD, <sup>1\*</sup> and He Cai, MD, PhD <sup>1\*</sup>

<sup>1</sup> Department of Cardiovascular Diseases, The First Hospital of Jilin University,  
Changchun China

**Short Title:** Association of *H. pylori* infection and CHD

#### **\* Correspondence**

Yang Zheng (zhengyang@jlu.edu.cn) and He Cai (caihe19@mails.jlu.edu.cn) are co-corresponding authors.

Postal address: Department of Cardiovascular Diseases, The First Hospital of Jilin University No. 1 Xinmin Ave, Changchun, China 130021

Telephone: +86-13596447220

**Word count:** 4908

## Abstract

**Background:** More than half of the world's population have been infected with *H. pylori*, however the relationship between *H. pylori* infection and coronary heart disease (CHD) is unknown.

**Methods:** This study used mendelian randomization (MR) analyses. The instrument variables for *H. pylori* infection were genetic variables (rs10004195 and rs368433) obtained from a published study. The outcome data included diagnosis, prognosis, and pathogenesis data for CHD, which were extracted from the public genome-wide association studies database, mainly from the CARDIoGRAMplusC4D consortium, UK Biobank, IEU database, and FinnGen database. MR analyses were performed per outcome database and were conducted by reverse analysis. Two step MR analyses were used to explore indirect pathogenic factors of *H. pylori* infection.

**Results:** Genetically-predicted *H. pylori* infection was causally associated with body mass index (BMI) ( $\beta$ , 0.022; 95% CI, 0.008–0.036;  $p$ -value = 0.001), but not with the diagnosis of CHD (OR, 0.991; 95%CI, 0.904–1.078;  $p$ -value = 0.842, IEU database; OR, 1.049; 95% CI, 0.980–1.118;  $p$ -value = 0.178, FinnGen database) and prognosis of CHD (OR, 0.999; 95% CI, 0.997–1.001;  $p$ -value = 0.391, IEU database; OR, 1.022; 95% CI, 0.922–1.123;  $p$ -value = 0.663, FinnGen database). The causal effect of *H. pylori* infection on CHD is mediated by BMI. Inverse MR showed no causal effect of CHD on *H. pylori* infection.

**Conclusions:** Our findings confirm the causal effect of *H. pylori* infection on CHD is mediated by BMI. Eradication or prevention of *H. pylori* infection may have a clinical

benefit for patients with CHD indirectly.

**Key words:** mendelian randomization, helicobacter pylori, coronary heart disease, inflammation, body mass index

## **Nonstandard Abbreviations and Acronyms**

CHD, coronary heart disease

GWAS, genome-wide association studies

H. pylori, helicobacter pylori

IVs, instrument variables

IVW, inverse variance weighted

MACE, major adverse cardiovascular events

MR, mendelian randomization

SNPs, single nucleotide polymorphisms

## Clinical Perspective

### What Is New?

- Genetically-predicted *H. pylori* infection was causally associated with body mass index, but not with the diagnosis and prognosis (major adverse cardiovascular events) of coronary heart disease.
- The causal effect of *H. pylori* infection on coronary heart disease is mediated by body mass index. Inverse mendelian randomization analyses showed no causal effect of coronary heart disease on *H. pylori* infection.

### What Are the Clinical Implications?

- Our findings confirm that the causal effect of *H. pylori* infection on coronary heart disease is partially mediated by body mass index.
- Eradication or prevention of *H. pylori* infection may have a clinical benefit for patients with CHD indirectly.

## Introduction

Coronary heart disease (CHD) is caused by atherosclerosis, including angina pectoris and myocardial infarction (MI), the leading cause of mortality in many countries. <sup>1</sup> The etiology, pathogenesis and prognosis of CHD are complex and have not been fully understood until now. *Helicobacter pylori* (*H. pylori*) is a Gram-negative bacterium that primarily inhabits the stomach and duodenum. <sup>2</sup> More than half of the world's population have been infected with *H. pylori*.<sup>3</sup> In addition to causing gastrointestinal diseases, <sup>4</sup> *H. pylori* can also induce some systemic reactions, such as abnormal glucose <sup>5</sup> and lipid metabolism, <sup>6</sup> blood hypercoagulability,<sup>7, 8</sup> and chronic inflammatory reactions,<sup>9-11</sup> and is accompanied by vitamin deficiency. <sup>12</sup> These systemic reactions may promote coronary arteriosclerosis, leading to the occurrence and development of CHD.

However, the relationship between *H. pylori* infection and CHD is controversial. Some studies have found that *H. pylori* infection is one of the main causes of CHD, and can lead to coronary artery endothelial damage by promoting the secretion of inflammatory factors, blood coagulation, and other mechanisms, which leads to atherosclerosis and CHD, and increases the incidence rate of restenosis in patients after percutaneous transluminal coronary angioplasty (PTCA). <sup>13-15</sup> The probability of myocardial infarction in patients with *H. pylori* infection is twice that of uninfected individuals.<sup>16</sup> However, some studies have found that *H. pylori* infection is not significantly related to the occurrence and degree of CHD. <sup>17, 18</sup> It is worth noting that

at present, the evidence for a link between *H. pylori* infection and CHD is based on observational studies, and there may be some unknown confounding factors that affect judgment of the results. To address this controversial clinical issue, a study that removes confounding factors to accurately determine the causal relationship between *H. pylori* infection and CHD is urgently needed.

Mendelian randomization (MR) has emerged as a popular epidemiological statistical method that can remove confounding factors and accurately determine the causal relationship between two variables. The method uses the public genome-wide association study (GWAS) database to obtain instrument variables (IVs) that are strongly related to exposure but are not related to outcomes or confounding factors. The IVs are usually single nucleotide polymorphisms (SNPs), and the causal relationship between exposure and outcomes can be accurately inferred using the IVs. In this study, we used *H. pylori* infection as the exposure and applied the bidirectional MR method to infer the relationship between *H. pylori* infection and the diagnosis, prognosis, and possible pathogenesis of CHD. We also used CHD as the exposure to explore the reverse causal relationship between CHD and *H. pylori* infection, two step MR analyses were used to explore indirect pathogenic factors of *H. pylori* infection, with the aim of clarifying this relationship and providing clinical suggestions for the diagnosis and treatment of CHD.

## Methods

## Study Design

For the current study, we used IVs as a proxy for exposure, then conducted MR to test the association between exposure and outcome.<sup>19</sup> MR is based on three principle assumptions: (1) correlation assumption: IVs are strongly correlated with exposure; (2) exclusivity hypothesis: IVs are not associated with outcomes; (3) independence hypothesis: IVs are independent of other confounding factors<sup>20</sup> (**Figure 1**).

## Data Sources Description

The genetic association of CHD was derived from the CARDIoGRAMplusC4D Consortium, which assembled 60,801 cases and 123,504 control subjects from 48 studies, and of which 77% of the participants were of European ancestry and 19% were of South and East Asian ancestry.<sup>21</sup> We also collected the summary statistics for CHD, MI and angina pectoris, which were derived from the FinnGen database (<https://www.finnngen.fi/en>).<sup>22</sup> *H. pylori* infection data were derived from the European Bioinformatics Institute (EBI) database (<https://gwas.mrcieu.ac.uk/datasets/ieu-b-4905/>) and included 1058 cases and 3625 controls. GWAS data were also collected to investigate the causal effect between *H. pylori* infection and the prognostic data for CHD, including major adverse cardiovascular events (MACE; Neale laboratory and FinnGen database), heart failure (Neale laboratory), heart arrhythmia, heart attack, stroke, target heart rate (HR) reached, and maximum HR data [MRC Integrated Epidemiology Unit (MRC-IEC),



<https://www.bristol.ac.uk/integrative-epidemiology>]. In addition, GWAS data on the possible pathogenesis between *H. pylori* and CHD were also obtained, including fasting blood glucose data from the EBI database, body mass index (BMI) data from the MRC-IEU database, and data on lipid traits from the UK Biobank database. Vitamin data were obtained from the MRC-IEU database. Inflammation data were downloaded from the public database IEU (<https://gwas.mrcieu.ac.uk/>). The GWAS data are presented in detail in **Table 1** and were approved by the author or the Consortium.

### **Selection of Genetic Instrumental Variables for *H. pylori* Infection**

The genetic IVs were acquired from previous literature. SNP rs368433 and SNP rs10004195 located in the Toll-like receptor 10 (*TLR10*) gene (4p14) and the Fc gamma RIIA (*FCGR2A*) gene (1q23.3), respectively, were reported to be strongly related to *H. pylori* infection as IVs<sup>23</sup>. Instrument strength was evaluated using the F-statistic for each allele, and if the F-statistic was greater than 10, it was considered that the potential weak instrument bias can be minimized. The F-statistic for each SNP was derived from the the following equation and was greater than 100, and could therefore be used for our analysis<sup>24 25</sup> (**Table S1**).

$$F = R^2 (N-2) / (1- R^2)$$

$$R^2 = 2 \times (1-MAF) \times MAF \times \beta^2$$

N: the sample size of the exposure dataset. R<sup>2</sup>: the proportion of variation explained

by IVs. MAF: minor allele frequency.

### **Selection of Genetic Instrumental Variables for CHD and BMI**

The genetic IVs for CHD and the potential pathogenesis of *H. pylori* infection were obtained from the GWAS summary statistics. Then, the following three steps were employed to screen out the strong correlation with CHD but not that with *H. pylori* infection and confounding factors, to ensure that the effect of each allele (containing each SNP) was the same. First, SNPs strongly related to exposure were screened ( $p < 5 \times 10^{-8}$ ). Second, independence was set to remove linkage disequilibrium (LD;  $r^2 < 0.001$ , window size = 10,000 kb,  $p < 5 \times 10^{-8}$ ) and calculate the statistical strength (F-statistical  $> 10$ ). Third, the exposure and outcome datasets were harmonized to ensure that the effect alleles belonged to the same allele. The SNPs screened by these strict procedures can be used as IVs for subsequent analysis (**Table S2**). The genetic IVs for BMI were obtained by the same screening method (**Table S3**).

### **Statistical Analysis and Data Visualization**

All analyses were undertaken using the R programming software (R4.1.2, <https://www.rproject.org/>). The primary MR analysis was conducted using the Wald ratio and the inverse variance weighted (IVW) method, and a two-sided p-value  $< 0.05$  was considered significant, and due to the multiple comparisons, we further applied a Bonferroni corrected threshold for statistical significance ( $0.05/\text{number of analyses}$ ) (**Table 2**)<sup>26</sup>. In the reverse MR analysis and two step MR analysis, because of the large number of IVs, we applied two complementary methods (MR-Egger and

weighted-median) to increase the stability of the results. MR analyses were performed using the R-based package “TwoSampleMR” (Version 0.5.6). Forest plots were generated using the “ggplot2” R package (version 3.4.0).

## RESULTS

### Causal Effect of *H. pylori* infection on the Diagnosis of CHD

Based on previous studies, SNP rs10004195 (T > A) and SNP rs368433 (T > C) are strongly related to *H. pylori* infection,<sup>24</sup> We therefore used the two SNPs as IVs of *H. pylori* infection to predict the relationship between *H. pylori* infection and the diagnosis of CHD, MI, and angina pectoris.<sup>23</sup> Genetically predicted *H. pylori* infection showed no association with the occurrence of CHD (IEU) [odds ratio (OR), 0.991; 95% confidence interval (CI), 0.904–1.078; *p*-value = 0.842], CHD (Finn) (OR, 1.049; 95% CI, 0.980–1.118; *p*-value = 0.178), angina pectoris (OR, 1.105; 95% CI, 1.019–1.191; *p*-value = 0.023) , or MI (OR, 0.993; 95% CI, 0.896–1.091; *p*-value = 0.889) under the IVW method. **(Figure 2, Table S4).**

### Causal Effect of *H. pylori* infection on the Prognosis of CHD

MR analyses were further performed to examine the causal association between *H. pylori* infection and the prognosis of CHD, including MACE, heart arrhythmia, heart attack, stroke, heart failure, target HR achieved, and maximum HR during fitness test. The analysis showed that *H. pylori* infection had no causal effect on MACE (OR, 0.999; 95% CI, 0.997–1.001; *p*-value = 0.391, IEU database; OR, 1.022; 95% CI, 0.922–1.123;

$p$ -value = 0.663, FinnGen database), heart arrhythmia (OR, 1.000; 95% CI, 0.999–1.001;  $p$ -value = 0.823), heart attack (OR, 0.998; 95% CI, 0.996–1.000;  $p$ -value = 0.124), stroke (OR, 0.999; 95% CI, 0.998–1.001;  $p$ -value = 0.525), heart failure (OR, 1.000; 95% CI, 0.999–1.001;  $p$ -value = 0.741), target HR achieved (OR, 0.994; 95% CI, 0.983–1.005;  $p$ -value = 0.252), or maximum HR (OR, 0.972; 95% CI, 0.937–1.007;  $p$ -value = 0.115) (Figure 3, Table S5).

### Causal Effect of *H. pylori* infection on the Pathogenesis of CHD

Based on previous research, we summarized the pathogenic mechanisms of *H. pylori* infection on CHD and these included abnormal glucose and lipid metabolism, vitamin deficiency, and chronic inflammatory reaction. To explore the causal relationship between *H. pylori* infection and pathogenesis of CHD, we used *H. pylori* infection as the exposure and pathogenesis as the outcome for MR analysis. In the MR analyses of abnormal glucose and lipid metabolism, *H. pylori* infection showed no association with fasting blood glucose levels ( $\beta$ , 0.006; 95% CI, -0.011–0.023;  $p$ -value = 0.511), Triglyceride(TG) ( $\beta$ , 0.005; 95% CI, -0.006–0.016;  $p$ -value = 0.409), High-density lipoprotein cholesterol (HDL-C) ( $\beta$ , -0.006; 95% CI, -0.047–0.035;  $p$ -value = 0.788), or low-density lipoprotein cholesterol (LDL-C) ( $\beta$ , 0.013; 95% CI, -0.026–0.051;  $p$ -value = 0.515). In the MR analysis of vitamin deficiency, we also obtained negative results, including vitamin C ( $\beta$ , -0.002; 95% CI, -0.006–0.002;  $p$ -value = 0.318), vitamin D ( $\beta$ , -0.0003; 95% CI, -0.003–0.002;  $p$ -value = 0.775), and vitamin B12 ( $\beta$ , 0.008; 95% CI, -0.029–0.044;  $p$ -value = 0.685). However, there was a significant causal effect

between *H. pylori* infection and BMI ( $\beta$ , 0.022; 95% CI, 0.008–0.036;  $p$ -value = 0.001), and there is a causal relationship between BMI and CHD. In the analyses of an inflammatory reaction, no positive results were obtained for interleukin families or tumor necrosis factor (**Figure 4, Table S6, and Table S7**).

### **Reverse Causal Effect of CHD on *H. pylori* Infection**

The IVs of CHD, MI, and angina pectoris were identified from the public GWAS summary data. Three MR analysis methods, namely, inverse variance weighted (IVW), weighted median, and MR-Egger, were used for this analysis. All three methods showed no significant causal relationship on *H. pylori* infection (**Figure 5, Table S8**).

### **Discussion**

In this study, we used large-scale public GWAS data to analyze the causal relationship between *H. pylori* infection and the risk of CHD using the MR method. The causal effect of *H. pylori* infection on CHD is mediated by BMI.

The association between *H. pylori* infection and CHD is currently controversial. Several studies have reported that *H. pylori* infection is related to the occurrence and prognosis of CHD.<sup>15, 27, 28</sup> A prospective study found that *H. pylori*-infected patients had an increased occurrence of CHD<sup>29</sup> and adverse events.<sup>27</sup> In other studies, MI patients infected with *H. pylori* had a higher mortality rate<sup>30</sup> and the probability of restenosis after PTCA was higher.<sup>13</sup> It has also been shown that MI has a reverse causal effect on *H. pylori*. Young people with MI have double the probability of *H.*

*pylori* infection as healthy individuals.<sup>31</sup> However, some studies have been unable to detect a correlation between the occurrence and development of CHD and *H. pylori* infection, especially among older individuals.<sup>32</sup> A prospective study on a small sample<sup>18</sup> and meta-analyses of five large samples<sup>18, 33</sup> have all provided evidence that *H. pylori* infection is not significantly related to the severity and prognosis of CHD. A prospective study involving 180 patients found that *H. pylori* infection is not significantly related to restenosis after PTCA.<sup>34</sup> The pathogenic link between *H. pylori* infection and CHD remains controversial. First, in terms of metabolism, the influence of *H. pylori* infection on glucose and lipid metabolism and BMI is controversial. With regard to lipids, a study found that *H. pylori* infection can reduce the level of HDL and increase the levels of LDL and TG.<sup>35</sup> However, other studies present the opposite findings. Meta-analyses and prospective studies of large samples have shown that eradication of *H. pylori* infection has no significant effect on the levels of HDL, TG, and LDL.<sup>6, 36</sup> In terms of glucose metabolism, evidence suggests that *H. pylori* infection may participate in the onset of diabetes and impaired glucose control in diabetes patients.<sup>37, 38</sup> Patients with *H. pylori* infection from different populations also reported higher levels of insulin resistance.<sup>39</sup> One study found that compared with the control group, the improvement in glucose homeostasis in diabetes patients after successful eradication of *H. pylori* infection was not statistically significant.<sup>40</sup> With regard to weight, eradication of *H. pylori* infection may increase the weight of children<sup>41</sup> and increase<sup>42</sup> or decrease<sup>43</sup> the weight of adults, and obese individuals show a higher prevalence of *H. pylori* infection<sup>44</sup>. Second, *H. pylori* infection causes

changes in the gastrointestinal microenvironment, which may impair the absorption of nutrients, leading to a lack of micronutrients. Poor vitamin absorption has been shown to be related to *H. pylori* infection<sup>45</sup>. Vitamin C and D levels are closely related to CHD, but the relationship between vitamins and *H. pylori* remains to be confirmed. Third, *H. pylori* can cause an inflammatory reaction. Chronic inflammation caused by *H. pylori* may have dual effects. On the one hand, low-grade inflammation is a common feature of obesity, diabetes, insulin resistance, and dyslipidemia and *H. pylori* may cause a chronic inflammatory reaction through abnormal metabolism.<sup>46</sup> On the other hand, *H. pylori* causes damage to the gastrointestinal tract,<sup>47</sup> stimulating the increase in IL levels<sup>10, 11</sup>. *H. pylori* infection has been associated with elevated levels of tumor necrosis factor and IL-6 in patients with CHD.<sup>48</sup> Conflicting data has also been reported regarding inflammation.<sup>49</sup> The factors involved in the pathogenesis of *H. pylori* infection, which include glucose and lipid metabolism, vitamin deficiency, and chronic inflammatory reactions, are all causes of CHD.

The controversy between *H. pylori* infection and CHD could be attributed to multiple reasons, such as differences in the race and age of the selected sample population, the small sample size, the low incidence of MACE, the detection method for *H. pylori* infection, and the different follow-up times. These confounding factors may lead to the poor statistical efficiency of the data and may affect the reliability of the experimental results.

This study found that *H. pylori* infection has no direct causal effect on the diagnosis

and prognosis of CHD. In the analysis of pathogenesis, *H. pylori* infection has a causal effect on BMI, and BMI has a causal effect on CHD. Therefore, the causal effect of *H. pylori* infection on CHD is mediated by BMI. However, *H. pylori* infection has no causal effect on inflammatory factors, vitamins, glucose and lipid metabolism and there is no reverse causal effect of CHD on *H. pylori* Infection.

This study used the MR method to reveal a bidirectional causal relationship between *H. pylori* infection and CHD for the first time, and could increase the recognition of pathogenic factors of CHD from the perspective of system biology. The advantage of the MR study is that the sample size is large, and it is a natural randomized controlled trial, which eliminates confounding factors. However, there are still limitations of this study. The GWAS of *H. pylori* infection is based on serological samples, which may not be truly representative of *H. pylori* infection. Furthermore, the samples were of european origin and therefore may not be representative of populations worldwide. Finally, the screening of IVs in this study was strict, which may have led to negative results.

## **Conclusions**

Our findings confirm that the causal effect of *H. pylori* infection on CHD is mediated by BMI. Therefore, eradication or prevention of *H. pylori* infection may have a clinical benefit for patients with CHD indirectly. However, it is not recommended that patients with CHD be screened for *H. pylori* infection.

## **Acknowledgement**



We thank the personnel at our centers participating in the research for their commitment and professionalism to this study.

### **Author Contributions**

Bing Li, Yang Zheng, and Yaoting Zhang analyzed the study data, Bing Li wrote the manuscript. He Cai and Yang Zheng provided ideas and supervised the research and edited the manuscript. All authors approved the submitted version.

### **Data Availability**

The datasets presented in this study can be downloaded from the public website (Table 1).

### **Sources of Funding**

None.

### **Disclosures**

None.

## References

1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. *Eur Heart J*. 2014;35:2950-9.
2. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *Lancet*. 1983;1:1273-5.
3. Hooi J, Lai WY, Ng WK, Suen M, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong V, Wu J, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. *Gastroenterology*. 2017;153:420-429.
4. de Brito BB, da Silva F, Soares AS, Pereira VA, Santos M, Sampaio MM, Neves P, de Melo FF. Pathogenesis and clinical management of Helicobacter pylori gastric infection. *World J Gastroenterol*. 2019;25:5578-5589.
5. Jeon CY, Haan MN, Cheng C, Clayton ER, Mayeda ER, Miller JW, Aiello AE. Helicobacter pylori infection is associated with an increased rate of diabetes. *Diabetes Care*. 2012;35:520-5.
6. Watanabe J, Hamasaki M, Kotani K. The Effect of Helicobacter pylori Eradication on Lipid Levels: A Meta-Analysis. *J Clin Med*. 2021;10.
7. Torgano G, Cosentini R, Mandelli C, Perondi R, Blasi F, Bertinieri G, Tien TV, Ceriani G, Tarsia P, Arosio C, et al. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. *Circulation*. 1999;99:1555-9.
8. Yusuf SW, Mishra RM. Effect of Helicobacter pylori infection on fibrinogen

- level in elderly patients with ischaemic heart disease. *Acta Cardiol.* 2002;57:317-22.
9. Kabir S. The role of interleukin-17 in the *Helicobacter pylori* induced infection and immunity. *Helicobacter.* 2011;16:1-8.
  10. Rocha GA, de Melo FF, Cabral M, de Brito BB, da Silva F, Queiroz D. Interleukin-27 is abrogated in gastric cancer, but highly expressed in other *Helicobacter pylori*-associated gastroduodenal diseases. *Helicobacter.* 2020;25:e12667.
  11. Rasool KH, Mahmood Alubadi AE, Al-Bayati I. The role of Serum Interleukin-4 and Interleukin-6 in *Helicobacter pylori*-infected patients. *Microb Pathog.* 2022;162:105362.
  12. Li WQ, Zhang JY, Ma JL, Li ZX, Zhang L, Zhang Y, Guo Y, Zhou T, Li JY, Shen L, et al. Effects of *Helicobacter pylori* treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. *BMJ.* 2019;366:l5016.
  13. Kowalski M. *Helicobacter pylori* (*H. pylori*) infection in coronary artery disease: influence of *H. pylori* eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of *H. pylori* specific DNA in human coronary atherosclerotic plaque. *J Physiol Pharmacol.* 2001;52:3-31.
  14. Vizzardì E, Bonadei I, Piovanelli B, Quinzani F, Ricci C, Lanzini A, Dei Cas L. *Helicobacter pylori* and ischemic heart disease. *Panminerva Med.*

- 2011;53:193-202.
15. Wang JW, Tseng KL, Hsu CN, Liang CM, Tai WC, Ku MK, Hung TH, Yuan LT, Nguang SH, Yang SC, et al. Association between Helicobacter pylori eradication and the risk of coronary heart diseases. *PLoS One*. 2018;13:e0190219.
  16. Rahmani Y, Mohammadi S, Babanejad M, Rai A, Zalei B, Shahmohammadi A. Association of Helicobacter Pylori with Presence of Myocardial Infarction in Iran: A Systematic Review and Meta-Analysis. *Ethiop J Health Sci*. 2017;27:433-440.
  17. Koenig W, Rothenbacher D, Hoffmeister A, Miller M, Bode G, Adler G, Hombach V, März W, Pepys MB, Brenner H. Infection with Helicobacter pylori is not a major independent risk factor for stable coronary heart disease: lack of a role of cytotoxin-associated protein A-positive strains and absence of a systemic inflammatory response. *Circulation*. 1999;100:2326-31.
  18. Rogha M, Dadkhah D, Pourmoghaddas Z, Shirneshan K, Nikvarz M, Pourmoghaddas M. Association of helicobacter pylori infection with severity of coronary heart disease. *ARYA Atheroscler*. 2012;7:138-41.
  19. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. *Eur J Epidemiol*. 2015;30:543-52.
  20. Emdin CA, Khera AV, Kathiresan S. Mendelian Randomization. *JAMA*. 2017;318:1925-1926.

21. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP, Hopewell JC, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet.* 2015;47:1121-1130.
22. Luo J, le Cessie S, van Heemst D, Noordam R. Diet-Derived Circulating Antioxidants and Risk of Coronary Heart Disease: A Mendelian Randomization Study. *J Am Coll Cardiol.* 2021;77:45-54.
23. Mayerle J, den Hoed CM, Schurmann C, Stolk L, Homuth G, Peters MJ, Capelle LG, Zimmermann K, Rivadeneira F, Gruska S, et al. Identification of genetic loci associated with *Helicobacter pylori* serologic status. *JAMA.* 2013;309:1912-20.
24. Liu Y, Xu H, Zhao Z, Dong Y, Wang X, Niu J. No evidence for a causal link between *Helicobacter pylori* infection and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study. *Front Microbiol.* 2022;13:1018322.
25. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol.* 2011;40:755-64.
26. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol.* 2013;37:658-65.
27. Shmueli H, Wattad M, Solodky A, Yahav J, Samra Z, Zafrir N. Association of *Helicobacter pylori* with coronary artery disease and myocardial infarction

- assessed by myocardial perfusion imaging. *Isr Med Assoc J*. 2014;16:341-6.
28. Fang Y, Fan C, Xie H. Effect of Helicobacter pylori infection on the risk of acute coronary syndrome: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2019;98:e18348.
  29. Liu J, Wang F, Shi S. Helicobacter pylori Infection Increase the Risk of Myocardial Infarction: A Meta-Analysis of 26 Studies Involving more than 20,000 Participants. *Helicobacter*. 2015;20:176-83.
  30. Alkout AM, Ramsay EJ, Mackenzie DA, Weir DM, Bentley AJ, Elton RA, Sutherland S, Busuttill A, Blackwell CC. Quantitative assessment of IgG antibodies to Helicobacter pylori and outcome of ischaemic heart disease. *FEMS Immunol Med Microbiol*. 2000;29:271-4.
  31. Danesh J, Youngman L, Clark S, Parish S, Peto R, Collins R. Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study. *BMJ*. 1999;319:1157-62.
  32. Pilotto A, Rumor F, Franceschi M, Leandro G, Novello R, Soffiati G, Scagnelli M, Di Mario F, Valerio G. Lack of association between Helicobacter pylori infection and extracardiac atherosclerosis in dyspeptic elderly subjects. *Age Ageing*. 1999;28:367-71.
  33. Danesh J. Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: meta-analyses of prospective studies. *Am Heart J*. 1999;138:S434-7.
  34. Schiele F, Batur MK, Seronde MF, Meneveau N, Sewoke P, Bassignot A,

- Couetdic G, Caulfield F, Bassand JP. Cytomegalovirus, Chlamydia pneumoniae, and Helicobacter pylori IgG antibodies and restenosis after stent implantation: an angiographic and intravascular ultrasound study. *Heart*. 2001;85:304-11.
35. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Association of Helicobacter pylori infection with elevated serum lipids. *Atherosclerosis*. 1999;142:207-10.
36. Elizalde JI, Piqué JM, Moreno V, Morillas JD, Elizalde I, Bujanda L, De Argila CM, Cosme A, Castiella A, Ros E. Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. *Aliment Pharmacol Ther*. 2002;16:577-86.
37. Kato M, Toda A, Yamamoto-Honda R, Arase Y, Sone H. Association between Helicobacter pylori infection, eradication and diabetes mellitus. *J Diabetes Investig*. 2019;10:1341-1346.
38. Mansori K, Moradi Y, Naderpour S, Rashti R, Moghaddam AB, Saed L, Mohammadi H. Helicobacter pylori infection as a risk factor for diabetes: a meta-analysis of case-control studies. *BMC Gastroenterol*. 2020;20:77.
39. Buzás GM. Metabolic consequences of Helicobacter pylori infection and eradication. *World J Gastroenterol*. 2014;20:5226-34.
40. Vafaeimanesh J, Rajabzadeh R, Ahmadi A, Moshtaghi M, Banikarim S, Hajiebrahimi S, Seyyedmajidi M. Effect of Helicobacter pylori eradication on glycaemia control in patients with type 2 diabetes mellitus and comparison of two therapeutic regimens. *Arab J Gastroenterol*. 2013;14:55-8.

41. Yang YJ, Sheu BS, Yang HB, Lu CC, Chuang CC. Eradication of *Helicobacter pylori* increases childhood growth and serum acylated ghrelin levels. *World J Gastroenterol*. 2012;18:2674-81.
42. Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P, Harvey RF. Randomised clinical trial: *Helicobacter pylori* eradication is associated with a significantly increased body mass index in a placebo-controlled study. *Aliment Pharmacol Ther*. 2011;33:922-9.
43. Kebapcilar L, Sari I, Renkal AH, Alacacioglu A, Yuksel A, Ilhan E, Alkan B, Yuksel D, Kozaci DL, Gunay N. The influence of *Helicobacter pylori* eradication on leptin, soluble CD40 ligand, oxidative stress and body composition in patients with peptic ulcer disease. *Intern Med*. 2009;48:2055-9.
44. Arslan E, Atilgan H, Yavaşoğlu I. The prevalence of *Helicobacter pylori* in obese subjects. *Eur J Intern Med*. 2009;20:695-7.
45. Franceschi F, Annalisa T, Teresa DR, Giovanna D, Ianiro G, Franco S, Viviana G, Valentina T, Riccardo LL, Antonio G. Role of *Helicobacter pylori* infection on nutrition and metabolism. *World J Gastroenterol*. 2014;20:12809-17.
46. Crewe C, An YA, Scherer PE. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. *J Clin Invest*. 2017;127:74-82.
47. Walduck A, Andersen LP, Raghavan S. Inflammation, Immunity, and Vaccines for *Helicobacter pylori* Infection. *Helicobacter*. 2015;20 Suppl 1:17-25.
48. Schumacher A, Seljeflot I, Lerkerød AB, Sommervoll L, Otterstad JE, Arnesen H.



Positive Chlamydia pneumoniae serology is associated with elevated levels of tumor necrosis factor alpha in patients with coronary heart disease.

*Atherosclerosis*. 2002;164:153-60.

49. Watanabe J, Kotani K. The effect of Helicobacter pylori eradication on C-reactive protein: results from a meta-analysis. *Arch Med Sci*. 2022;18:958-964.

**Table 1.** Details of the studies included in the Mendelian randomization analyses.


Phenotype	Consortium /Author/Database	Ethnicity	Sample Size (cases/ controls)	Year	SNPs(n)	Web Source
<i>H. polyri</i> infection	EBI	European	1,058/3,625	2021	7,247,045	<a href="https://gwas.mrcieu.ac.uk/datasets/ieub-4905/">https://gwas.mrcieu.ac.uk/datasets/ieub-4905/</a>
CHD	CARDIoGRAMplusC4D	Mixed	60801 /123,504	2015	9,455,779	<a href="https://gwas.mrcieu.ac.uk/datasets/ieua-7/">https://gwas.mrcieu.ac.uk/datasets/ieua-7/</a>
CHD	FinnGen study	European	30,952/187,840	2021	16,380,466	<a href="https://gwas.mrcieu.ac.uk/datasets/finn-b-19_ISCHHEART/">https://gwas.mrcieu.ac.uk/datasets/finn-b-19_ISCHHEART/</a>
MI	FinnGen study	European	12,801/187,840	2021	16,380,433	<a href="https://gwas.mrcieu.ac.uk/datasets/finn-b-19_MI/">https://gwas.mrcieu.ac.uk/datasets/finn-b-19_MI/</a>
Angina pectoris	FinnGen study	European	18,168 /187,840	2021	16,380,426	<a href="https://gwas.mrcieu.ac.uk/datasets/finn-b-19_ANGINA/">https://gwas.mrcieu.ac.uk/datasets/finn-b-19_ANGINA/</a>
FBG	EBI	European	58,074 participants	2012	2,599,409	<a href="https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST005186/">https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST005186/</a>
TG	UK Biobank	European	441,016 participants	2020	12,321,875	<a href="https://gwas.mrcieu.ac.uk/datasets/ieub-111/">https://gwas.mrcieu.ac.uk/datasets/ieub-111/</a>
HDL	UK Biobank	European	403,943 participants	2020	12,321,875	<a href="https://gwas.mrcieu.ac.uk/datasets/ieub-109/">https://gwas.mrcieu.ac.uk/datasets/ieub-109/</a>
LDL	UK Biobank	European	440,546 participants	2020	12,321,875	<a href="https://gwas.mrcieu.ac.uk/datasets/ieub-110/">https://gwas.mrcieu.ac.uk/datasets/ieub-110/</a>
BMI	MRC-IEU	European	454,884 participants	2018	9,851,867	<a href="https://gwas.mrcieu.ac.uk/datasets/ukb-b-2303/">https://gwas.mrcieu.ac.uk/datasets/ukb-b-2303/</a>
Vitamin C	MRC-IEU	European	39,880/ 420,471	2018	9,851,867	<a href="https://gwas.mrcieu.ac.uk/datasets/ukb-b-15175/">https://gwas.mrcieu.ac.uk/datasets/ukb-b-15175/</a>
Vitamin D	MRC-IEU	European	17,879/ 442,472	2018	9,851,867	<a href="https://gwas.mrcieu.ac.uk/datasets/ukb-b-12648/">https://gwas.mrcieu.ac.uk/datasets/ukb-b-12648/</a>
Vitamin B12	MRC-IEU	European	64979 participants	2018	9,851,867	<a href="https://gwas.mrcieu.ac.uk/datasets/ukb-b-19524/">https://gwas.mrcieu.ac.uk/datasets/ukb-b-19524/</a>
Interleukin-18	Folkersen L	European	21758 participants	2020	13,102,515	<a href="https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST90012024/">https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST90012024/</a>
Interleukin-6	Folkersen L	European	21758 participants	2020	11,782,139	<a href="https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST90012005/">https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST90012005/</a>
Interleukin-8	Folkersen L	European	21758 participants	2020	12,717,989	<a href="https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST90011994/">https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST90011994/</a>
Interleukin-4	Ahola-Olli AV	European	8,124 participants	2016	9,786,064	<a href="https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST004453/">https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST004453/</a>
Interleukin-10	Ahola-Olli AV	European	7681 participants	2016	9,793,415	<a href="https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST004444/">https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST004444/</a>
TNF- $\alpha$	Ahola-Olli AV	European	3454 participants	2016	9,500,449	<a href="https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST004426/">https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST004426/</a>
MACEs	Neale lab	European	10,157/ 351,037	2018	13,295,130	<a href="https://gwas.mrcieu.ac.uk/datasets/ukb-d-19_CHD/">https://gwas.mrcieu.ac.uk/datasets/ukb-d-19_CHD/</a>
MACEs	FinnGen study	European	21,012/ 197,780	2021	16,380,466	<a href="https://gwas.mrcieu.ac.uk/datasets/finn-b-19_CHD/">https://gwas.mrcieu.ac.uk/datasets/finn-b-19_CHD/</a>
Death	FinnGen study	European	7,563/ 211,229	2021	16,380,466	<a href="https://gwas.mrcieu.ac.uk/datasets/finn-b-19_K_CARDIAC/">https://gwas.mrcieu.ac.uk/datasets/finn-b-19_K_CARDIAC/</a>

Heart arrhythmia	MRC-IEU	European	2,545/460,388	2018	9,851,867	<a href="https://gwas.mrcieu.ac.uk/datasets/ukb-b-3703/">https://gwas.mrcieu.ac.uk/datasets/ukb-b-3703/</a>
Heart attack	MRC-IEU	European	10693/451,187	2018	9,851,867	<a href="https://gwas.mrcieu.ac.uk/datasets/ukb-b-11590/">https://gwas.mrcieu.ac.uk/datasets/ukb-b-11590/</a>
Stroke	MRC-IEU	European	7,055/454,825	2018	9,851,867	<a href="https://gwas.mrcieu.ac.uk/datasets/ukb-b-8714/">https://gwas.mrcieu.ac.uk/datasets/ukb-b-8714/</a>
Heart failure	Neale lab	European	1405/359,789	2018	9,858,439	<a href="https://gwas.mrcieu.ac.uk/datasets/ukb-d-19_HEARTFAIL/">https://gwas.mrcieu.ac.uk/datasets/ukb-d-19_HEARTFAIL/</a>
Target HR	MRC-IEU	European	6,995/61,431	2018	9,851,867	<a href="https://gwas.mrcieu.ac.uk/datasets/ukb-b-16609/">https://gwas.mrcieu.ac.uk/datasets/ukb-b-16609/</a>
Maximum HR	MRC-IEU	European	68,409 participants	2018	9,851,867	<a href="https://gwas.mrcieu.ac.uk/datasets/ukb-b-14461/">https://gwas.mrcieu.ac.uk/datasets/ukb-b-14461/</a>


Abbreviations: BMI: body mass index; CHD, coronary heart disease; CRP, C-reactive protein; FBG, fast blood glucose; HDL-C; high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; MACEs, major adverse cardiovascular events; Maximum HR, maximum heart rate during fitness test; MI, myocardial infarction; Target HR, target heart rate achieved; TG, triglycerides; TNF- $\alpha$ , tumor necrosis factor- $\alpha$ .

**Table 2.** The Bonferroni corrected threshold for statistical significance in the diagnosis, prognosis and pathogenesis of CHD


Outcome	Number of analyses	Bonferroni corrected threshold
Diagnosis	4	0.0125
Prognosis	9	0.0056
Pathogenesis	14	0.0036




**Figure 1.** Schematic representation of the MR study on the causal relationship between *H. pylori* infection and CHD. CHD, coronary heart disease; *Helicobacter pylori*; IVs, instrument variants; *H. pylori*, helicobacter pylori; SNP, single-nucleotide polymorphisms.



**Figure 2.** Mendelian randomization result of the effect of *H. pylori* infection on the diagnosis of CHD. CHD, Coronary heart disease; *H. pylori*, helicobacter pylori; MI, Myocardial infarction; OR, odds ratio.




**Figure 3.** Mendelian randomization result of the effect of *H. pylori* infection on the prognosis of CHD. CHD, Coronary heart disease; *H. pylori*, helicobacter pylori; MACEs, major adverse cardiovascular events; Maximum HR, Maximum heart rate during fitness test; OR, odds ratio; Target HR achieved, reach target heart rate.



**Figure 4.** Two step Mendelian randomization result of the effect of *H. pylori* infection on CHD (the pathogenic mechanism of CHD). BMI: body mass index; CRP, C-reactive protein; FBG, fast blood glucose; *H. pylori*, helicobacter pylori; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; OR, odds ratio. TG, triglycerides; TNF- $\alpha$ , tumor necrosis factor- $\alpha$ . Dark blue dots represent statistical differences in *P* values.





**Figure 5.** Mendelian randomization result of the effect of CHD on *H. pylori* infection. CHD, coronary heart disease; *H. pylori*, helicobacter pylori; MI, myocardial infarction; OR, odds ratio.

## Supplemental Material

Tables S1-S8